EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials

EHVA’s multidisciplinary research platforms encompass all aspects of vaccine development from early-stage discovery to clinical trials

Goals of the Discovery Platform include generating novel vaccine candidates. Participating organisations specialise in inducing potent neutralising antibodies and non-neutralising antibodies and T-cell responses.

Goals of the Immune Profiling Platform include developing methods to that provide a profile of the immune response generated by a vaccine candidate.

Goals of the Data Management/Integration/Down-Selection Platform include providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines.

Goals of the Clinical Trials Platform include accelerating the clinical development of novel vaccines and developing tools to predict poor or low efficacy of a candidate early in the process.

News

  • EHVA initiates a clinical trial to test a novel therapeutic vaccine and immunotherapy drug

    The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland.

    Press release

  • Next Consortium Meeting of EHVA June 2018

    Next Consortium Meeting of EHVA will be held 21st & 22nd of June at the School of Medecine, Barcelona

  • 1st December 2018 World Aids Day
europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032